



Market Trend



The market tried to find a direction during the week and finally closed on the downside. The main indices declined by around 2% on weekly basis in low investors' activity. The market lost steam after the strong beginning of the month and SOFIX is 5% up as compared to July, 2010. The non-consolidated 1H 2010 reports had short-term influence on the market, but until the end of August the holding companies should announce their consolidated reports, which may attract the investors' attention. The market probably will stay around the flat line this week as the summer moods still pre-dominated.

Trading Activity



The volumes remained around BGN 1 million, mainly due to block deals. Sopharma (3JR) and its subsidiaries were among the companies with the largest turnover. On Tuesday, 192 000 shares of the pharmaceutical company were transferred in one deal at the end of the session, probably as a part of the recent buying back procedure.

**SOFIX**

Stock	Last Price	Weekly Change	Bid	Ask
Albena	68.00	-5.56%	68.00	70.00
Bulgarian-American Credit Bank	11.10	0.00%	10.40	10.70
Central Cooperative Bank	1.21	-4.04%	1.22	1.24
Chimimport	2.44	1.67%	2.40	2.44
Corporate Commercial Bank	61.00	-0.81%	60.65	62.00
ELARG	0.56	-3.79%	0.57	0.60
Enemona	7.00	-3.50%	6.90	7.00
Eurohold Bulgaria	0.89	-4.60%	0.88	0.89
First Investment Bank	1.95	-2.35%	1.95	1.99
Holding Roads	1.50	-0.66%	1.48	1.50
Industrial Holding Bulgaria	1.38	-1.79%	1.38	1.42
Kaolin	4.00	-3.59%	4.00	4.18
Lead and Zink Complex	11.38	1.58%	11.03	11.30
M+S Hydraulic	4.95	1.23%	4.62	4.98
Monbat	6.50	-1.52%	6.50	6.57
Neochim	23.50	-2.08%	23.10	23.40
Orgachim	85.72	-0.32%	85.72	86.55
Sopharma	3.91	-3.08%	3.90	3.96
Sparky Eltos	1.60	-5.72%	1.56	1.60
Trace Group Hold	50.00	-3.10%	50.00	51.39

Chimimport (6C4) was the best SOFIX's performer during the week with 1.67% added in weekly basis. The company managed to set around top 10 by turnover but in lower volumes as compared to the usual turnover on the position. On the other side was its subsidiary Central Cooperative Bank (4CF), which was the worst performer among the banking sector.

The Board of Directors of Sopharma started the first procedure for buying back of company shares in compliance with a decision at the GMS of the company on June 23, 2010. The amount of shares subject to redemption is up to 3 960 000 (3% of all shares out-standing) for period not longer than 24 months. The minimum price is BGN 3.50 and the maximum price is BGN 5.50.

The low liquidity still defines the direction of the market rather than purposive buy or sell orders.

**News**

- **20 August 2010:** Enemona (E4A) will lead an extraordinary GMS on September, 20. Voting right will be entitled to all shareholders registered in the Central Depository by September 03, 2010.
- **20 August 2010:** Corporate Commercial Bank (6C9) will announce a consolidated financial statement for its activities as of the second quarter of 2010, its balance sheet and profit and loss account for July 2010, on August 23, 2010.

**Upcoming Events**

- **24 August 2010:** Bulgarian National Bank will announce the credit portfolio of the banking system and the Gross external debt as of June, 2010.
- **26 August 2010:** BNB will announce the interest rates statistic.
- **27 August 2010:** National Statistic Institute will report the Business climate indicator August.

**Macro-economy**

- The Current account for June is on positive territory – EUR 117 million as compare to deficit of EUR 281 million for June 2009. Since the beginning of the year the current account deficit is 1.8% of GDP as compared to 7.8% of GDP for the same period 2009.
- The index of producer prices in agriculture decreases by 4.6% in the second quarter of 2010 as compared to the same quarter 2009. Decreases were registered in the crop production by 9.8%, and in the livestock the prices are at the same level as the corresponding quarter of the previous year. The index of prices of means of production used in agriculture in the second quarter of 2010 is 1.7% below the same quarter of 2009.

**Disclaimer**

**Analyst Certification:** The research analyst(s) certifies that: (1) all of the views expressed in this document accurately reflect his or her personal views about any and all of the subject securities or issuers; (2) no part of any of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this document.

**Financial Interest:** ELANA Trading may trade or own shares of the analyzed companies. The research analyst(s) is not holding shares of the analyzed companies, unless otherwise noted.

**Regulatory Authority:** Financial Supervisory Commission, *Shar Planina* Street 33, 1303 Sofia, Bulgaria

**Information Disclosure:** All reasonable care has been taken to ensure the facts stated are accurate and opinions given are fair and reasonable. Our recommendations are based on information available to the public that we consider to be reliable but for the completeness and accuracy of which we assume no liability. Neither ELANA Trading, nor its directors, officers or employees shall in any way be responsible for its contents. The views expressed may differ from the views of other firm departments or representatives. Additional information is available upon request. Unless otherwise noted, sources for all information in charts and tables are ELANA Trading's calculations.

**Risks for Investors:** Information in this document should not be regarded as an offer to buy or sell any financial instruments. The investment possibilities discussed in this document may not be suitable for certain investors depending on their specific investment objectives and time horizon or in the context of their overall financial situation. In particular, the risks associated with an investment in the securities or the financial instruments under discussion are not explained in its entirety. The prices or values of the securities may go down as well as up and can fluctuate and fall against the investor. The securities or investments may cause the investor to lose the amount invested. Past performance is not a guide to future performance. Changes in exchange rates may have an adverse effect on the value, price or income of the securities or investments.

**Valuation Methods:** Company valuations are based on the following methods: multiple-based (P/E, P/B, EV/EBITDA), historical valuation approaches, peer comparisons, discount models (DCF, DDM) or asset-based evaluation methods. Valuation models are dependent on macroeconomic factors, including interest rates, foreign exchange rates, prices of raw materials, and any expectations about the economy, the market sentiment. The valuation is based on expectations that might change rapidly and without notice, depending on developments specific to individual industries and countries. Recommendations and target prices derived from the models might therefore change accordingly. The application of models depends on forecasts of a range of economic variables, thus there is a range of reasonable variations within models. Any valuation is dependent upon inputs that are based on the subjective opinion of the analysts carrying out this valuation.

**Recommendations:** Analyst(s) recommendations are based on the specific factors for the company, sector, country and global developments, as compared to market indices. Recommendations and opinions reflect ELANA Trading's expectations over the 12-month period following publication from the perspective of long-only investment clients. ELANA Trading reserves the right to express different or contrary recommendations and opinions for different timescales or for other types of investment client. Except as otherwise noted, expected performance over next 12 months vary for different recommendations for Bulgarian stocks as follows:

<b>Outperform</b>	More than 5% higher as compared to SOFIX and BG40 performance
<b>Market Perform</b>	Market performance, +/-5% as compared to SOFIX and BG40
<b>Underperform</b>	More than 5% lower as compared to SOFIX and BG40 performance

**Frequency of Recommendations:** No schedule of recommendations is available. The frequency of recommendations depends on specific factors to individual companies and the opinion of the analyst(s) for the necessity of minor or major changes.

For more information about the current recommendations, please visit ELANA Trading web page: [http://www.elana.net/analysis/reports/bul\\_f\\_pazar\\_7/LIST\\_Recommendations.pdf](http://www.elana.net/analysis/reports/bul_f_pazar_7/LIST_Recommendations.pdf)

**For more information, please contact:**

Research analyst  
Tsvetoslav Tsachev  
Tamara Becheva

Phone:  
+359 2 810 00 23  
+359 2 810 00 27

E-mail:  
[tsachev@elana.net](mailto:tsachev@elana.net)  
[becheva@elana.net](mailto:becheva@elana.net)

Internet:  
[www.elana.net](http://www.elana.net)  
[www.elana.net](http://www.elana.net)